Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis September 12, 2016
Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update August 15, 2016
Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 July 6, 2016
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016 June 17, 2016
Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis June 16, 2016
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update May 16, 2016
Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis April 12, 2016
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND March 31, 2016
